Nafoxidine--an antiestrogen for the treatment of breast cancer.
Nafoxidine is a nonsteroidal antiestrogen available as an investigational agent from the Investigational Drug Branch of the National Cancer Institute. It has been used effectively in the treatment of breast cancer patients. A cumulative response rate of 31% is reported for a total of 200 patients treated with this drug. Most patients have been treated with a dose of 60 mg three times a day. Side effects include dryness of skin, photosensitivity reactions and, less commonly, partial hair loss. There is a strong correlation of response to nafoxidine with the presence of estrogen receptor in the tumor and also with the response to previous hormonal treatment. Nafoxidine is a useful addition to the list of hormonal treatments in the therapy of breast cancer.
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007057:Ichthyosis / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000188:drug therapy; D051379:Mice; D009256:Nafoxidine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011759:Pyrrolidines / Q000627:therapeutic use*; D051381:Rats
D011759:Pyrrolidines; D009256:Nafoxidine